Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aytu BioPharma Inc. (AYTU : NSDQ)

• Company Description    Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $2.18 Daily Weekly Monthly 20 Day Moving Average: 190,106 shares Shares Outstanding: 8.98 (millions) Market Capitalization: $19.57 (millions) Beta: 0.13 52 Week High: $2.87 52 Week Low: $0.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.80% 6.74% 12 Week 115.82% 82.13% Year To Date 28.24% 20.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7900 E. UNION AVENUE SUITE 920 - DENVER,CO 80237 USA ph: 720-437-6580 fax: - rselhorn@aytubio.com http://www.aytubio.com

• General Corporate Information    Officers Joshua R. Disbrow - Chief Executive Officer and Chairman Mark K. Oki - Chief Financial Officer; Corporate Secretary and T John A. Donofrio, Jr. - Lead Independent Director Carl C. Dockery - Director Abhinav Jain - Director Peer Information Aytu BioPharma Inc. (CORR.) Aytu BioPharma Inc. (RSPI) Aytu BioPharma Inc. (CGXP) Aytu BioPharma Inc. (BGEN) Aytu BioPharma Inc. (GTBP) Aytu BioPharma Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 054754858 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/25/25 Share - Related Items Shares Outstanding: 8.98 Most Recent Split Date: 1.00 (0.05:1) Beta: 0.13 Market Capitalization: $19.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/25/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: 0.28 EPS Growth vs. Year Ago Period: 138.46% vs. Previous Quarter: 171.43% Sales Growth vs. Year Ago Period: 2.55% vs. Previous Quarter: 13.75% ROE 06/30/25 - - 03/31/25 - 3.51 12/31/24 - -19.30 ROA 06/30/25 - - 03/31/25 - 0.91 12/31/24 - -4.80 Current Ratio 06/30/25 - - 03/31/25 - 1.03 12/31/24 - 0.98 Quick Ratio 06/30/25 - - 03/31/25 - 0.87 12/31/24 - 0.81 Operating Margin 06/30/25 - - 03/31/25 - 1.56 12/31/24 - -8.36 Net Margin 06/30/25 - - 03/31/25 - 2.37 12/31/24 - -7.62 Pre-Tax Margin 06/30/25 - - 03/31/25 - -0.78 12/31/24 - -8.90 Book Value 06/30/25 - - 03/31/25 - 5.66 12/31/24 - 5.00 Inventory Turnover 06/30/25 - - 03/31/25 - 2.54 12/31/24 - 2.26 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.27 12/31/24 - 0.32 Debt-to-Capital 06/30/25 - - 03/31/25 - 21.46 12/31/24 - 24.50

Powered by Zacks Investment Research ©